Advanced Cell Models – Webinars and Online Events

In this webinar, we will explore how retinal organoids are used as a platform to assess the safety and efficacy of retinal gene therapy treatments.

Non-alcoholic fatty liver disease (NAFLD) is a spectrum of metabolic disorders that affects 25% of our global population. 20% of those with NAFLD develop non-alcoholic steatohepatitis (NASH), which can result in cirrhosis and liver cancer.

Despite continued research and development efforts, not one NASH therapeutic agent has made it to market yet. Traditional preclinical tests have repeatedly failed to predict human drug efficacy as they inadequately recreate the complexity and multifaceted nature of this human disease. As a result, NASH is poised to become a global health and economic burden.

Is it time to increase your chances of clinical success with a new human-relevant approach to drug discovery and development?

In this webinar, Dr. Holz will discuss the background of cell-to-cell communication, highlighting studies and recent developments in the field as well as exploring the clinical implications of these studies on cancer biology and patient care.

The administration of drugs via inhalation into the lungs is superior to many other methods of delivery because our lungs provide a large surface area for absorption, access to the whole blood volume and comparatively little metabolic activity. Currently, there are limited in vitro models in which the absorption and permeability of drugs across the lung and into systemic circulation can be precisely measured.

In this webinar, Dr. Emily Richardson will describe novel lung-on-a-chip (LOAC), otherwise known as lung microphysiolological system, models of the alveoli and bronchi which can be used to accurately predict drug pharmacokinetics, allowing for more rapid, precise and cost-effective analysis of compounds.

To explore how this challenge might be approached, 780 human Liver-Chips were analyzed to determine their ability to predict drug-induced liver injury caused by small molecules.

This inaugural online symposium will explore the tools and techniques being used to study diseases in the lab. Focus will be given to cell culture, organ-on-a-chip and organoid models, as well as, how innovations are enabling researchers to elucidate the underlying biological mechanisms of disease and support diagnostic and therapeutic development.

This webinar will explore how we can isolate and expand patient-derived intestinal organoids in culture. By combining these organoids with scaffolds, we can generate functional intestinal mucosal grafts which demonstrate a proof-of-concept for subsequent clinical translation and future use in patients.

In this webinar, Dr. Yassen Abbas will discuss how CN-Bio’s gut–liver MPS can be used for in vitro determination of oral bioavailability.

The powerful combination of stem-cell derived organoids and single-cell multiomics is revolutionizing developmental cell biology.

With safety concerns being the major cause for failures in Phase 1/2 clinical trials, it’s essential to develop more predictive models within preclinical drug discovery to improve data translatability.